565 reports of this reaction
1.9% of all LIFITEGRAST reports
#12 most reported adverse reaction
VISUAL IMPAIRMENT is the #12 most commonly reported adverse reaction for LIFITEGRAST, manufactured by Bausch & Lomb Incorporated. There are 565 FDA adverse event reports linking LIFITEGRAST to VISUAL IMPAIRMENT. This represents approximately 1.9% of all 29,776 adverse event reports for this drug.
Patients taking LIFITEGRAST who experience visual impairment should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VISUAL IMPAIRMENT is a less commonly reported adverse event for LIFITEGRAST, but still significant enough to appear in the safety profile.
In addition to visual impairment, the following adverse reactions have been reported for LIFITEGRAST:
The following drugs have also been linked to visual impairment in FDA adverse event reports:
VISUAL IMPAIRMENT has been reported as an adverse event in 565 FDA reports for LIFITEGRAST. This does not prove causation, but indicates an association observed in post-market surveillance data.
VISUAL IMPAIRMENT accounts for approximately 1.9% of all adverse event reports for LIFITEGRAST, making it a notable side effect.
If you experience visual impairment while taking LIFITEGRAST, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.